# The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

> **NCT03236636** · PHASE3 · UNKNOWN · sponsor: **Beijing Shenogen Biomedical Co., Ltd** · enrollment: 312 (estimated)

## Conditions studied

- Advanced HBV-Related Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Icaritin
- **DRUG:** HUACHANSU PIAN

## Key facts

- **NCT ID:** NCT03236636
- **Lead sponsor:** Beijing Shenogen Biomedical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-08
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2021-01-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236636, "The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03236636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*